MCID: EXT048
MIFTS: 31

Extranodal Nasal Nk/t Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Skin diseases, Blood diseases, Immune diseases

Aliases & Classifications for Extranodal Nasal Nk/t Cell Lymphoma

MalaCards integrated aliases for Extranodal Nasal Nk/t Cell Lymphoma:

Name: Extranodal Nasal Nk/t Cell Lymphoma 53 59
Nasal T/natural Killer-Cell Lymphoma 53 59
Angiocentric T-Cell Lymphoma 53 59
Lethal Midline Granuloma 53 59
Nk/t-Cell Lymphoma 53 59
Nktcl 53 59
Nasal Type Extranodal Nk/t-Cell Lymphoma 73
Nasal and Nasal-Type Nk/t-Cell Lymphoma 73
Granuloma, Lethal Midline 73

Characteristics:

Orphanet epidemiological data:

59
extranodal nasal nk/t cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA86879
UMLS via Orphanet 74 C0018197 C0392788
MESH via Orphanet 45 D054391
ICD10 via Orphanet 34 C86.0
ICD10 33 C86 C86.0

Summaries for Extranodal Nasal Nk/t Cell Lymphoma

NIH Rare Diseases : 53 Extranodal nasal NK/T cell lymphoma (NKTCL) is a rare type of cancer. The term extranodal is used because this form of lymphoma is found outside of the traditional lymph node groupings. It mainly affects men around 50 years of age, and usually arises in the nose, paranasal sinuses (paranasal sinuses are cavities (spaces) or small tunnels. located around or near the nose), orbits or upper airway, and that can present with a nasal mass, nasal bleeding, nasal obstruction,  a hole in the palate, and mid-facial and/or upper airway destructive lesions. In advanced disease stages, which are associated with a poor prognosis, NKTCL may affect other organs, but usually without enlarged nodes in the body. The treatment depends on the extent of disease and usually involves radiotherapy and chemotherapy.

MalaCards based summary : Extranodal Nasal Nk/t Cell Lymphoma, also known as nasal t/natural killer-cell lymphoma, is related to lethal midline granuloma and malignant histiocytosis, and has symptoms including fever and malaise. The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and lymph node.

Wikipedia : 76 Extranodal NK/T-cell lymphoma, nasal type which was known as angiocentric lymphoma in the REAL... more...

Related Diseases for Extranodal Nasal Nk/t Cell Lymphoma

Diseases related to Extranodal Nasal Nk/t Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 lethal midline granuloma 12.8
2 malignant histiocytosis 11.4
3 lymphoma 10.3
4 autoimmune lymphoproliferative syndrome, type v 10.1

Symptoms & Phenotypes for Extranodal Nasal Nk/t Cell Lymphoma

UMLS symptoms related to Extranodal Nasal Nk/t Cell Lymphoma:


fever, malaise

Drugs & Therapeutics for Extranodal Nasal Nk/t Cell Lymphoma

Drugs for Extranodal Nasal Nk/t Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
2
Cisplatin Approved Phase 4,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Ifosfamide Approved Phase 4,Phase 2,Phase 1 3778-73-2 3690
4
Mesna Approved, Investigational Phase 4,Phase 2 3375-50-6 598
5
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
7
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 130167-69-0
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Mechlorethamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 51-75-2 4033
10 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
11
Isophosphamide mustard Phase 4,Phase 2,Phase 1 0
12 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
13 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14
asparaginase Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 N-Methylaspartate Phase 4,Phase 2
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
38 Aspartic Acid Nutraceutical Phase 4,Phase 2
39
alemtuzumab Approved, Investigational Phase 3,Phase 2 216503-57-0
40
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
41
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
42
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
43
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
44
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
45
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
46
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
47
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
48
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
49
Prednisone Approved, Vet_approved Phase 3,Not Applicable 53-03-2 5865
50
Levoleucovorin Approved, Investigational Phase 3,Not Applicable 68538-85-2

Interventional clinical trials:

(show top 50) (show all 199)
# Name Status NCT ID Phase Drugs
1 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
2 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
3 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
4 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
8 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
9 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
10 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
11 MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Recruiting NCT02631239 Phase 3 Methotrexate;Etoposide;Dexamethasone;Pegaspargase
12 PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage Recruiting NCT02918747 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Dexamethasone;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
13 PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma Recruiting NCT02085655 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Methotrexate;Dexamethasone;Thalidomide
14 Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Terminated NCT02359162 Phase 3 Gemcitabine;Oxaliplatin;Pegaspargase;Etoposide;Vincristine;Doxorubicin;Cyclophosphamide;Prednisone
15 Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Unknown status NCT01667302 Phase 2 Radiotherapy followed by chemotherapy
16 Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma Unknown status NCT01007526 Phase 2
17 New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma Unknown status NCT00933673 Phase 2 L-asp, DXM, IFO, VP-16, DDP
18 Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma Unknown status NCT00568607 Phase 2 IFO, VP-16, DDP, DXM
19 MESA Treatment for NK/T Cell Lymphoma Unknown status NCT01933282 Phase 2 MESA chemotherapy;MESA
20 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
21 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
22 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
23 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
24 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Completed NCT02825147 Phase 2 Pegaspargase;Methotrexate;Dexamethasone;Etoposide
25 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
26 L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma Completed NCT00854425 Phase 2 L-asparaginase
27 Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01238159 Phase 2
28 A Phase II Study of Nasal NK/T-cell Lymphoma Completed NCT00292695 Phase 2
29 Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma Completed NCT00418535 Phase 2 Concurrent Radiotherapy (RT)/cisplatin, VIPD
30 Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Completed NCT02276248 Phase 2 GDP chemotherapy
31 Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas Completed NCT00374699 Phase 1, Phase 2 Velcade
32 Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma Completed NCT00283985 Phase 2 Kidrolase;Methotrexate;Dexamethasone;Erwinase
33 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
34 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
35 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
37 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
38 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
39 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
40 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
41 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
42 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
43 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
44 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
45 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
46 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
47 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
48 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2 Everolimus
49 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
50 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade

Search NIH Clinical Center for Extranodal Nasal Nk/t Cell Lymphoma

Genetic Tests for Extranodal Nasal Nk/t Cell Lymphoma

Anatomical Context for Extranodal Nasal Nk/t Cell Lymphoma

MalaCards organs/tissues related to Extranodal Nasal Nk/t Cell Lymphoma:

41
T Cells, Bone, Lymph Node, Bone Marrow, Liver, Skin, Kidney

Publications for Extranodal Nasal Nk/t Cell Lymphoma

Articles related to Extranodal Nasal Nk/t Cell Lymphoma:

# Title Authors Year
1
EBV-associated T/NK-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal NK/T-cell lymphoma but shows distinctive stem cell-like phenotype. ( 25382618 )
2014
2
Extranodal nasal NK/T-cell lymphoma: a rare oral presentation and FASN, CD44 and GLUT-1 expression. ( 23969921 )
2013
3
Extranodal nasal NK/T-cell lymphoma with dissemination to the central nervous system: a case report. ( 21053585 )
2010
4
Lethal midline granuloma revisited: nasal T/Natural-killer cell lymphoma. ( 10561195 )
1999
5
Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. ( 9207410 )
1997

Variations for Extranodal Nasal Nk/t Cell Lymphoma

Cosmic variations for Extranodal Nasal Nk/t Cell Lymphoma:

9
(show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5968693 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.3364C>T p.R1122C 16:2079636-2079636 9
2 COSM43707 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.779C>T p.S260F 17:7674184-7674184 9
3 COSM10654 TP53 haematopoietic and lymphoid tissue,orbit,lymphoid neoplasm,NK-T cell lymphoma c.637C>T p.R213* 17:7674894-7674894 9
4 COSM44117 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.775G>A p.D259N 17:7674188-7674188 9
5 COSM43606 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.734G>A p.G245D 17:7674229-7674229 9
6 COSM43596 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.841G>A p.D281N 17:7673779-7673779 9
7 COSM11084 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.517G>A p.V173M 17:7675095-7675095 9
8 COSM44289 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.497C>T p.S166L 17:7675115-7675115 9
9 COSM10660 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.818G>A p.R273H 17:7673802-7673802 9
10 COSM44706 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.420C>T p.T140T 17:7675192-7675192 9
11 COSM6932 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.733G>A p.G245S 17:7674230-7674230 9
12 COSM10739 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.481G>A p.A161T 17:7675131-7675131 9
13 COSM44312 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.511G>A p.E171K 17:7675101-7675101 9
14 COSM44028 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.431A>G p.Q144R 17:7675181-7675181 9
15 COSM43602 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.706T>G p.Y236D 17:7674257-7674257 9
16 COSM44413 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.484A>G p.I162V 17:7675128-7675128 9
17 COSM5968689 STAT3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.1975A>C p.I659L 17:42322408-42322408 9
18 COSM5393247 SMARCB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.749C>T p.T250M 22:23816890-23816890 9
19 COSM4006667 KMT2C haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.3340T>C p.C1114R 7:152222666-152222666 9
20 COSM5945890 AMER1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.1570T>C p.C524R 23:64191717-64191717 9
21 COSM5945887 ALK haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.1816A>G p.R606G 2:29296889-29296889 9

Expression for Extranodal Nasal Nk/t Cell Lymphoma

Search GEO for disease gene expression data for Extranodal Nasal Nk/t Cell Lymphoma.

Pathways for Extranodal Nasal Nk/t Cell Lymphoma

GO Terms for Extranodal Nasal Nk/t Cell Lymphoma

Sources for Extranodal Nasal Nk/t Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....